Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

Abstract

PURPOSE To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor. PATIENTS AND METHODS In phase I, the MTD of once daily oral doses of tosedostat in hematologic malignancies was defined. In phase II, the therapeutic activity of the maximum… (More)
DOI: 10.1200/JCO.2009.27.6295

Topics

6 Figures and Tables

Cite this paper

@article{Lwenberg2010PhaseIC, title={Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.}, author={Bob L{\"{o}wenberg and Gareth J Morgan and Gert Jan Ossenkoppele and Alan K. Burnett and Pierre Zach{\'e}e and Ulrich Duehrsen and Daan Dierickx and Carsten M{\"{u}ller-Tidow and P. Sonneveld and Utz Krug and Elisabeth Bone and Nicol{\'a}s Flores and Alison F Richardson and Leon Hooftman and Chris Jenkins and Sonja Zweegman and Faith Elizabeth Davies}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2010}, volume={28 28}, pages={4333-8} }